Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

In-Situ Hybridization Market by Technique (Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)), by Application (Cancer Diagnosis, Immunology, Neuroscience, Cytology, Infectious Diseases) and by End User (Molecular Diagnostic Laboratories, Pharmaceutical Biotechnology Companies, Contract Research Organizations (CROS), Academic Research Institutions): Global Opportunity Analysis and Industry Forecast, 2023-2032

A02558

Pages: NA

Charts: NA

Tables: NA

In-situ hybridization utilizes a labeled probe of complementary RNA, DNA, or modified nucleic acid to localize particular DNA or RNA sequence. In addition, in-situ hybridization indicates the localization of gene expression in their cellular environment. The two types of in situ hybridization namely fluorescence in situ hybridization (FISH), and chromogenic in situ hybridization (CISH) are used to identify the position of genes, which offer useful insights regarding tumors. The major drivers that fuel the growth of the market are increase in cancer prevalence, rise in awareness about cancer along with technology advancements in cancer therapeutics, and increase in government initiatives. In contrast, availability of better technologies, such as high-throughput whole genome sequencing and microarray, and others restrain the growth of the global in-situ hybridization market.

This report segments the global in situ hybridization market based on technique, application, end user, and region. Based on technique, it is categorized into fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). Based on application, it is classified into cancer diagnosis, immunology, neuroscience, cytology, and infectious diseases. Based on end user, it is bifurcated molecular diagnostic laboratories, pharmaceutical & biotechnology companies, contract research organizations (CROS), and academic & research institutions. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players of the in-situ hybridization market are Abbott Laboratories, Inc., F. Hoffmann-La Roche AG, Leica Biosystems Nussloch GmbH, Agilent Technologies, Thermo Fisher Scientific, Inc., Merck KGaA, PerkinElmer, Inc., Exiqon A/S, BioGenex Laboratories, Inc., Advanced Cell Diagnostics, Inc., and Bio SB Inc.

Key Benefits

  • The study provides an in-depth analysis of the global in situ hybridization market, with current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by product type assists in understanding the various forms of in situ hybridization available.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

 Key Market Segments

  • By Technique
    • Fluorescence In-Situ Hybridization (FISH)
      • DNA-FISH
      • RNA-FISH
    • Chromogenic In-Situ Hybridization (CISH)
  • By Application
    • Cancer Diagnosis
    • Immunology
    • Neuroscience
    • Cytology
    • Infectious Diseases
  • By End User
    • Molecular Diagnostic Laboratories
    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROS)
    • Academic & Research Institutions
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Abbott Laboratories, Inc.
  • Agilent Technologies
  • BioGenex Laboratories, Inc.
  • Bio SB Inc.
  • Merck KGaA
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche AG
  • Exiqon A/S
  • dvanced Cell Diagnostics, Inc.
  • Leica Biosystems Nussloch GmbH

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: IN-SITU HYBRIDIZATION MARKET, BY TECHNIQUE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Technique

    • 4.2. Fluorescence In-Situ Hybridization (FISH)

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. DNA-FISH

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. RNA-FISH

        • 4.2.4.1. Market Size and Forecast

    • 4.3. Chromogenic In-Situ Hybridization (CISH)

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: IN-SITU HYBRIDIZATION MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Cancer Diagnosis

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Immunology

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Neuroscience

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Cytology

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Infectious Diseases

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: IN-SITU HYBRIDIZATION MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Molecular Diagnostic Laboratories

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Pharmaceutical And Biotechnology Companies

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Contract Research Organizations (CROS)

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Academic And Research Institutions

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: IN-SITU HYBRIDIZATION MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Technique

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. In-situ Hybridization Market

        • 7.2.6.1. Market Size and Forecast, By Technique
        • 7.2.6.2. Market Size and Forecast, By Application
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada In-situ Hybridization Market

        • 7.2.7.1. Market Size and Forecast, By Technique
        • 7.2.7.2. Market Size and Forecast, By Application
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico In-situ Hybridization Market

        • 7.2.8.1. Market Size and Forecast, By Technique
        • 7.2.8.2. Market Size and Forecast, By Application
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Technique

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France In-situ Hybridization Market

        • 7.3.6.1. Market Size and Forecast, By Technique
        • 7.3.6.2. Market Size and Forecast, By Application
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany In-situ Hybridization Market

        • 7.3.7.1. Market Size and Forecast, By Technique
        • 7.3.7.2. Market Size and Forecast, By Application
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy In-situ Hybridization Market

        • 7.3.8.1. Market Size and Forecast, By Technique
        • 7.3.8.2. Market Size and Forecast, By Application
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain In-situ Hybridization Market

        • 7.3.9.1. Market Size and Forecast, By Technique
        • 7.3.9.2. Market Size and Forecast, By Application
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK In-situ Hybridization Market

        • 7.3.10.1. Market Size and Forecast, By Technique
        • 7.3.10.2. Market Size and Forecast, By Application
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia In-situ Hybridization Market

        • 7.3.11.1. Market Size and Forecast, By Technique
        • 7.3.11.2. Market Size and Forecast, By Application
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe In-situ Hybridization Market

        • 7.3.12.1. Market Size and Forecast, By Technique
        • 7.3.12.2. Market Size and Forecast, By Application
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Technique

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China In-situ Hybridization Market

        • 7.4.6.1. Market Size and Forecast, By Technique
        • 7.4.6.2. Market Size and Forecast, By Application
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan In-situ Hybridization Market

        • 7.4.7.1. Market Size and Forecast, By Technique
        • 7.4.7.2. Market Size and Forecast, By Application
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India In-situ Hybridization Market

        • 7.4.8.1. Market Size and Forecast, By Technique
        • 7.4.8.2. Market Size and Forecast, By Application
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea In-situ Hybridization Market

        • 7.4.9.1. Market Size and Forecast, By Technique
        • 7.4.9.2. Market Size and Forecast, By Application
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia In-situ Hybridization Market

        • 7.4.10.1. Market Size and Forecast, By Technique
        • 7.4.10.2. Market Size and Forecast, By Application
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand In-situ Hybridization Market

        • 7.4.11.1. Market Size and Forecast, By Technique
        • 7.4.11.2. Market Size and Forecast, By Application
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia In-situ Hybridization Market

        • 7.4.12.1. Market Size and Forecast, By Technique
        • 7.4.12.2. Market Size and Forecast, By Application
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia In-situ Hybridization Market

        • 7.4.13.1. Market Size and Forecast, By Technique
        • 7.4.13.2. Market Size and Forecast, By Application
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific In-situ Hybridization Market

        • 7.4.14.1. Market Size and Forecast, By Technique
        • 7.4.14.2. Market Size and Forecast, By Application
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Technique

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil In-situ Hybridization Market

        • 7.5.6.1. Market Size and Forecast, By Technique
        • 7.5.6.2. Market Size and Forecast, By Application
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa In-situ Hybridization Market

        • 7.5.7.1. Market Size and Forecast, By Technique
        • 7.5.7.2. Market Size and Forecast, By Application
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia In-situ Hybridization Market

        • 7.5.8.1. Market Size and Forecast, By Technique
        • 7.5.8.2. Market Size and Forecast, By Application
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE In-situ Hybridization Market

        • 7.5.9.1. Market Size and Forecast, By Technique
        • 7.5.9.2. Market Size and Forecast, By Application
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina In-situ Hybridization Market

        • 7.5.10.1. Market Size and Forecast, By Technique
        • 7.5.10.2. Market Size and Forecast, By Application
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA In-situ Hybridization Market

        • 7.5.11.1. Market Size and Forecast, By Technique
        • 7.5.11.2. Market Size and Forecast, By Application
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Abbott Laboratories, Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. F. Hoffmann-La Roche AG

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Leica Biosystems Nussloch GmbH

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Agilent Technologies

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Thermo Fisher Scientific, Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Merck KGaA

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. PerkinElmer, Inc.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Exiqon A/S

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. BioGenex Laboratories, Inc.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Dvanced Cell Diagnostics, Inc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Bio SB Inc.

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL IN-SITU HYBRIDIZATION MARKET, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL IN-SITU HYBRIDIZATION MARKET FOR FLUORESCENCE IN-SITU HYBRIDIZATION (FISH), BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL IN-SITU HYBRIDIZATION MARKET FOR CHROMOGENIC IN-SITU HYBRIDIZATION (CISH), BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL IN-SITU HYBRIDIZATION MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL IN-SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL IN-SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL IN-SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL IN-SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL IN-SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL IN-SITU HYBRIDIZATION MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL IN-SITU HYBRIDIZATION MARKET FOR MOLECULAR DIAGNOSTIC LABORATORIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL IN-SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL IN-SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL IN-SITU HYBRIDIZATION MARKET FOR ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL IN-SITU HYBRIDIZATION MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA IN-SITU HYBRIDIZATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 20. U.S. IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 21. U.S. IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. U.S. IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 23. CANADA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 24. CANADA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 25. CANADA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE IN-SITU HYBRIDIZATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. ITALY IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 40. ITALY IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. ITALY IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. UK IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 46. UK IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. UK IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC IN-SITU HYBRIDIZATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 58. CHINA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 59. CHINA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. CHINA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. INDIA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 65. INDIA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. INDIA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA IN-SITU HYBRIDIZATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 98. UAE IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 99. UAE IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 100. UAE IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA IN-SITU HYBRIDIZATION, BY TECHNIQUE, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA IN-SITU HYBRIDIZATION, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA IN-SITU HYBRIDIZATION, BY END USER, 2025-2033 ($MILLION)
  • TABLE 107. ABBOTT LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 108. ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 109. ABBOTT LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 110. ABBOTT LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 111. ABBOTT LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 113. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 114. F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 115. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 116. F. HOFFMANN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. LEICA BIOSYSTEMS NUSSLOCH GMBH: KEY EXECUTIVES
  • TABLE 118. LEICA BIOSYSTEMS NUSSLOCH GMBH: COMPANY SNAPSHOT
  • TABLE 119. LEICA BIOSYSTEMS NUSSLOCH GMBH: OPERATING SEGMENTS
  • TABLE 120. LEICA BIOSYSTEMS NUSSLOCH GMBH: PRODUCT PORTFOLIO
  • TABLE 121. LEICA BIOSYSTEMS NUSSLOCH GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. AGILENT TECHNOLOGIES: KEY EXECUTIVES
  • TABLE 123. AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 124. AGILENT TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 125. AGILENT TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 126. AGILENT TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
  • TABLE 128. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 129. THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 130. THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 131. THERMO FISHER SCIENTIFIC, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. MERCK KGAA: KEY EXECUTIVES
  • TABLE 133. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 134. MERCK KGAA: OPERATING SEGMENTS
  • TABLE 135. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 136. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. PERKINELMER, INC.: KEY EXECUTIVES
  • TABLE 138. PERKINELMER, INC.: COMPANY SNAPSHOT
  • TABLE 139. PERKINELMER, INC.: OPERATING SEGMENTS
  • TABLE 140. PERKINELMER, INC.: PRODUCT PORTFOLIO
  • TABLE 141. PERKINELMER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. EXIQON A/S: KEY EXECUTIVES
  • TABLE 143. EXIQON A/S: COMPANY SNAPSHOT
  • TABLE 144. EXIQON A/S: OPERATING SEGMENTS
  • TABLE 145. EXIQON A/S: PRODUCT PORTFOLIO
  • TABLE 146. EXIQON A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. BIOGENEX LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 148. BIOGENEX LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 149. BIOGENEX LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 150. BIOGENEX LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 151. BIOGENEX LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. DVANCED CELL DIAGNOSTICS, INC.: KEY EXECUTIVES
  • TABLE 153. DVANCED CELL DIAGNOSTICS, INC.: COMPANY SNAPSHOT
  • TABLE 154. DVANCED CELL DIAGNOSTICS, INC.: OPERATING SEGMENTS
  • TABLE 155. DVANCED CELL DIAGNOSTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 156. DVANCED CELL DIAGNOSTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. BIO SB INC.: KEY EXECUTIVES
  • TABLE 158. BIO SB INC.: COMPANY SNAPSHOT
  • TABLE 159. BIO SB INC.: OPERATING SEGMENTS
  • TABLE 160. BIO SB INC.: PRODUCT PORTFOLIO
  • TABLE 161. BIO SB INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-SITU HYBRIDIZATION MARKET SEGMENTATION
  • FIGURE 2. GLOBAL IN-SITU HYBRIDIZATION MARKET
  • FIGURE 3. SEGMENTATION IN-SITU HYBRIDIZATION MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN IN-SITU HYBRIDIZATION MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIN-SITU HYBRIDIZATION MARKET
  • FIGURE 11. IN-SITU HYBRIDIZATION MARKET SEGMENTATION, BY BY TECHNIQUE
  • FIGURE 12. IN-SITU HYBRIDIZATION MARKET FOR FLUORESCENCE IN-SITU HYBRIDIZATION (FISH), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. IN-SITU HYBRIDIZATION MARKET FOR CHROMOGENIC IN-SITU HYBRIDIZATION (CISH), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. IN-SITU HYBRIDIZATION MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. IN-SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. IN-SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. IN-SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. IN-SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. IN-SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. IN-SITU HYBRIDIZATION MARKET SEGMENTATION, BY BY END USER
  • FIGURE 21. IN-SITU HYBRIDIZATION MARKET FOR MOLECULAR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. IN-SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. IN-SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. IN-SITU HYBRIDIZATION MARKET FOR ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: IN-SITU HYBRIDIZATION MARKET
  • FIGURE 31. TOP PLAYER POSITIONING, 2024
  • FIGURE 32. ABBOTT LABORATORIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. ABBOTT LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. ABBOTT LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. F. HOFFMANN-LA ROCHE AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. LEICA BIOSYSTEMS NUSSLOCH GMBH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. LEICA BIOSYSTEMS NUSSLOCH GMBH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. LEICA BIOSYSTEMS NUSSLOCH GMBH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. AGILENT TECHNOLOGIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. AGILENT TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. AGILENT TECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. MERCK KGAA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. MERCK KGAA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. PERKINELMER, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. PERKINELMER, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. PERKINELMER, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. EXIQON A/S: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. EXIQON A/S: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. EXIQON A/S: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. BIOGENEX LABORATORIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. BIOGENEX LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. BIOGENEX LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. DVANCED CELL DIAGNOSTICS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. DVANCED CELL DIAGNOSTICS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. DVANCED CELL DIAGNOSTICS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 62. BIO SB INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 63. BIO SB INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 64. BIO SB INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
In-Situ Hybridization Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved